307 related articles for article (PubMed ID: 32588182)
1. COVID-19 in dimethyl fumarate-treated patients with multiple sclerosis.
Mantero V; Abate L; Basilico P; Balgera R; Salmaggi A; Nourbakhsh B; Cordano C
J Neurol; 2021 Jun; 268(6):2023-2025. PubMed ID: 32588182
[No Abstract] [Full Text] [Related]
2. COVID-19 in multiple sclerosis patients treated with dimethyl fumarate.
Capone F; Ferraro E; Motolese F; Di Lazzaro V
J Neurol; 2021 Sep; 268(9):3132-3134. PubMed ID: 33611610
[No Abstract] [Full Text] [Related]
3. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
Iaffaldano P; Lucisano G; Manni A; Paolicelli D; Patti F; Capobianco M; Brescia Morra V; Sola P; Pesci I; Lus G; De Luca G; Lugaresi A; Cavalla P; Montepietra S; Maniscalco GT; Granella F; Ragonese P; Vianello M; Brambilla L; Totaro R; Toscano S; Malucchi S; Petracca M; Moiola L; Ferraro D; Lepore V; Mosconi P; Ponzio M; Tedeschi G; Comi G; Battaglia MA; Filippi M; Amato MP; Trojano M;
Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046084
[TBL] [Abstract][Full Text] [Related]
4. [Dimethylfumarate in the treatment of relapsing-remitting multiple sclerosis].
Popova EV; Boyko AN; Orlova EV
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(10 Pt 2):68-72. PubMed ID: 28139614
[TBL] [Abstract][Full Text] [Related]
5. Multiple sclerosis: Dimethyl fumarate is coming of age.
Tintoré M; Sastre-Garriga J
Nat Rev Neurol; 2016 Aug; 12(8):436-7. PubMed ID: 27448183
[No Abstract] [Full Text] [Related]
6. Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β.
Simpson-Yap S; Pirmani A; De Brouwer E; Peeters LM; Geys L; Parciak T; Helme A; Hillert J; Moreau Y; Edan G; Spelman T; Sharmin S; McBurney R; Schmidt H; Bergmann A; Braune S; Stahmann A; Middleton R; Salter A; Bebo B; van der Walt A; Butzkueven H; Ozakbas S; Karabudak R; Boz C; Alroughani R; Rojas JI; van der Mei I; Sciascia do Olival G; Magyari M; Alonso R; Nicholas R; Chertcoff A; Zabalza A; Arrambide G; Nag N; Descamps A; Costers L; Dobson R; Miller A; Rodrigues P; Prčkovska V; Comi G; Kalincik T
Mult Scler Relat Disord; 2022 Oct; 66():104072. PubMed ID: 35917745
[TBL] [Abstract][Full Text] [Related]
7. NICE approval of dimethyl fumarate could benefit thousands living with relapsing-remitting multiple sclerosis.
Boulicault D; Duddy M
Neurodegener Dis Manag; 2015; 5(1):7-10. PubMed ID: 25711449
[No Abstract] [Full Text] [Related]
8. Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis.
Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö
J Neurol; 2021 Mar; 268(3):941-949. PubMed ID: 32974794
[TBL] [Abstract][Full Text] [Related]
9. Dimethyl Fumarate: A Review in Relapsing-Remitting MS.
Blair HA
Drugs; 2019 Dec; 79(18):1965-1976. PubMed ID: 31784875
[TBL] [Abstract][Full Text] [Related]
10. [Dimethyl fumarate (tecfidera) is the first line treatment choice in patients with remitting multiple sclerosis].
Shmidt TE
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11):140-145. PubMed ID: 29265100
[TBL] [Abstract][Full Text] [Related]
11. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H
Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
[TBL] [Abstract][Full Text] [Related]
13. Fulminant rebound of relapsing-remitting multiple sclerosis after discontinuation of dimethyl fumarate: A case report.
Harmel P; Schlunk F; Harms L
Mult Scler; 2018 Jul; 24(8):1131-1133. PubMed ID: 29708444
[TBL] [Abstract][Full Text] [Related]
14. Allergy and dimethyl fumarate treatment in a patient with multiple sclerosis.
Gelibter S; Orrico M; Moiola L; Dagna L; Filippi M; Yacoub MR
J Neurol Sci; 2020 Nov; 418():117104. PubMed ID: 32871512
[No Abstract] [Full Text] [Related]
15. First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study.
Maniscalco GT; Saccà F; Lanzillo R; Annovazzi P; Baroncini D; Binello E; Repice A; Perini P; Clerico M; Mataluni G; Bonavita S; La Gioia S; Gutierrez LP; Laroni A; Frau J; Cocco E; Torri Clerici V; Zarbo IR; Sartori A; Signoriello E; Rasia S; Cordioli C; Stromillo ML; Cerqua R; Pontecorvo S; Di Sapio A; Grasso R; Barone S; Lavorgna L; Barrilà C; Landi D; Russo CV; Frigeni B; Ippolito D; Turano G; Carmisciano L; Sormani MP; Signori A
Mult Scler Relat Disord; 2020 Jul; 42():102059. PubMed ID: 32208344
[TBL] [Abstract][Full Text] [Related]
16. [Clinical guidelines for the use of dimethyl fumarate in relapsing-remitting multiple sclerosis].
Alifirova VM; Boiko AN; Vlasov YV; Davydovskaya MV; Zakharova MN; Malkova NA; Popova EV; Sivertseva SA; Spirin NN; Khachanova NV; Shmidt ТЕ
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(1):97-102. PubMed ID: 28252608
[TBL] [Abstract][Full Text] [Related]
17. Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study.
Naismith RT; Wundes A; Ziemssen T; Jasinska E; Freedman MS; Lembo AJ; Selmaj K; Bidollari I; Chen H; Hanna J; Leigh-Pemberton R; Lopez-Bresnahan M; Lyons J; Miller C; Rezendes D; Wolinsky JS;
CNS Drugs; 2020 Feb; 34(2):185-196. PubMed ID: 31953790
[TBL] [Abstract][Full Text] [Related]
18. Alopecia associated with dimethyl fumarate treatment for multiple sclerosis.
Abičić A; Adamec I; Habek M
Wien Med Wochenschr; 2023 Sep; 173(11-12):287-289. PubMed ID: 36920580
[TBL] [Abstract][Full Text] [Related]
19. Transient hair loss during treatment with dimethyl-fumarate for multiple sclerosis.
Losavio FA; Lucchini M; De Fino C; Mirabella M; Nociti V
Mult Scler Relat Disord; 2016 May; 7():68-9. PubMed ID: 27237761
[TBL] [Abstract][Full Text] [Related]
20. Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis.
Yadav SK; Soin D; Ito K; Dhib-Jalbut S
J Mol Med (Berl); 2019 Apr; 97(4):463-472. PubMed ID: 30820593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
